MA26763A1 - Composition pharmaceutique d'aerosols contenant hfa 237 & hfa 134a - Google Patents

Composition pharmaceutique d'aerosols contenant hfa 237 & hfa 134a

Info

Publication number
MA26763A1
MA26763A1 MA26203A MA26203A MA26763A1 MA 26763 A1 MA26763 A1 MA 26763A1 MA 26203 A MA26203 A MA 26203A MA 26203 A MA26203 A MA 26203A MA 26763 A1 MA26763 A1 MA 26763A1
Authority
MA
Morocco
Prior art keywords
hfa
pharmaceutical composition
inhaler
aerosols containing
aerosol
Prior art date
Application number
MA26203A
Other languages
English (en)
Inventor
David Lewis
Brian Meakin
Gaetano Brambilla
Raffaella Garzia
David Ganderton
Paolo Ventura
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MA26763A1 publication Critical patent/MA26763A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA26203A 1998-11-25 2001-05-22 Composition pharmaceutique d'aerosols contenant hfa 237 & hfa 134a MA26763A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998MI002558A IT1303788B1 (it) 1998-11-25 1998-11-25 Formulazioni di aerosol medicinali.

Publications (1)

Publication Number Publication Date
MA26763A1 true MA26763A1 (fr) 2004-12-20

Family

ID=11381136

Family Applications (1)

Application Number Title Priority Date Filing Date
MA26203A MA26763A1 (fr) 1998-11-25 2001-05-22 Composition pharmaceutique d'aerosols contenant hfa 237 & hfa 134a

Country Status (22)

Country Link
US (2) US6713047B1 (fr)
EP (1) EP1133277B1 (fr)
JP (1) JP2002530316A (fr)
KR (1) KR100794060B1 (fr)
CN (1) CN1177582C (fr)
AT (1) ATE368450T1 (fr)
AU (1) AU770529B2 (fr)
BR (1) BR9916865A (fr)
CA (1) CA2352483C (fr)
CY (1) CY1106904T1 (fr)
DE (1) DE69936730T2 (fr)
DK (1) DK1133277T3 (fr)
ES (1) ES2289832T3 (fr)
IL (1) IL143293A0 (fr)
IT (1) IT1303788B1 (fr)
MA (1) MA26763A1 (fr)
NO (1) NO330195B1 (fr)
NZ (1) NZ511923A (fr)
PT (1) PT1133277E (fr)
TR (1) TR200101442T2 (fr)
WO (1) WO2000030607A1 (fr)
ZA (1) ZA200104220B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6739333B1 (en) 1999-05-26 2004-05-25 Boehringer Ingelheim Pharma Kg Stainless steel canister for propellant-driven metering aerosols
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
JP2003509359A (ja) 1999-09-11 2003-03-11 グラクソ グループ リミテッド プロピオン酸フルチカゾンの医薬製剤
JP2003518484A (ja) * 1999-12-24 2003-06-10 グラクソ グループ リミテッド サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤
IT1317720B1 (it) * 2000-01-07 2003-07-15 Chiesi Farma Spa Dispositivo per la somministrazione di aerosol dosati pressurizzati inpropellenti idrofluoroalcani.
IT1318514B1 (it) * 2000-05-12 2003-08-27 Chiesi Farma Spa Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari.
US20060257324A1 (en) 2000-05-22 2006-11-16 Chiesi Farmaceutici S.P.A. Pharmaceutical solution formulations for pressurised metered dose inhalers
EE05167B1 (et) * 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
GB2367011A (en) * 2000-08-26 2002-03-27 Glaxo Group Ltd Metered dose inhaler for salmeterol
DK1273292T3 (da) * 2001-07-02 2004-10-04 Chiesi Farma Spa Optimeret tobramycinformulering til aerosoldannelse
DK3384931T3 (da) * 2002-03-01 2019-09-16 Chiesi Farm Spa Superfin formoterolformulering
EP1340503A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formule d'une solution pour aerosol contenant des dérivés d'esters de 3,17 estratrien pour administration pulmonale
EP1340492A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique
EP1415647A1 (fr) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Beta-2-agonistes à activité de longue durée dans une formulation ultrafine
US7311894B2 (en) 2002-03-28 2007-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg HFA suspension formulations containing an anticholinergic
ES2275778T3 (es) * 2002-06-06 2007-06-16 Chiesi Farmaceutici S.P.A. Solubilizacion de farmacos en propulsores de hfa mediante emulsiones.
EP1452179A1 (fr) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Nouveau combination d'un puissant agoniste beta 2 de longue duree et un corticosteroid
KR101113003B1 (ko) 2003-03-20 2012-02-24 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 추진제로 하이드로-플루오로-알칸을 사용하는 계량 흡입기용 제형
EP1915985A1 (fr) 2003-03-20 2008-04-30 Boehringer Ingelheim Pharmaceuticals Inc. Formulation pour une dose mesurée utilisant des hydro-fluoro-alcanes en tant que propulseurs
US20060178394A1 (en) * 2003-04-14 2006-08-10 Staniforth John N Pharmaceutical compositions comprising apomorphine for pulmonary inhalation
US20080118442A1 (en) * 2003-09-10 2008-05-22 Map Pharmaceuticals, Inc. Aerosol Formulations for Delivery of Dihydroergotamine to the Systemic Circulations Via Pulmonary Inhalation
AR041873A1 (es) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab Una formulacion farmaceutica en aerosol adecuada para la inhalacion oral o nasal que contienen glucocorticoides en solucion estable al almacenamiento; un metodo para estabilzar formulaciones y uso de un agente estabilizante
SE0303179D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
IL177103A0 (en) * 2004-02-27 2006-12-10 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP1595531A1 (fr) * 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Formulation d'une solution pharmaceutique stable pour aérosols doseurs sous pression
CN1583170A (zh) * 2004-06-10 2005-02-23 安米 用于抗病毒抗耐药菌的人溶菌酶药物及其制法
EP1809243B2 (fr) 2004-07-02 2022-06-08 Boehringer Ingelheim International GmbH Formulations de suspensions aerosol contenant tg 227 ea en tant qu'agent propulseur
DE102006017320A1 (de) 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
EP2011534A1 (fr) * 2007-07-03 2009-01-07 CHIESI FARMACEUTICI S.p.A. Actionneur d'inhalateur à dosage mesuré
WO2011150441A1 (fr) * 2010-06-03 2011-12-08 Wholesome Biopharm Pty Ltd Formulation d'aérosol médical comprenant de la ribavirine
KR101803121B1 (ko) * 2010-08-03 2017-11-29 키에시 파르마슈티시 엣스. 피. 에이. 포스포디에스테라제 억제제를 포함하는 약학적 제제
US20140377189A1 (en) * 2013-06-19 2014-12-25 Map Pharmaceuticals, Inc. Pulmonary administration of rotigotine
US20160310410A1 (en) 2015-04-24 2016-10-27 Glenmark Specialty S.A. Pharmaceutical compositions comprising arformoterol and glycopyrronium
CN114796166A (zh) * 2021-01-29 2022-07-29 北京远大九和药业有限公司 一种含有萜烯类挥发油的气雾剂及其制备方法
CN114522143B (zh) * 2022-02-22 2026-02-06 暨南大学 用于吸入气雾剂的低制冷效应复合抛射剂及其制备方法和应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH89518A (de) * 1919-03-22 1921-06-01 Croning Johannes Der Türdicke entsprechend einstellbares Gehäuse für Zylinderschlösser.
US3095355A (en) * 1961-10-12 1963-06-25 Revlon Aerosol composition
US3860618A (en) * 1967-08-08 1975-01-14 Philip Saxton Hartley Chromone
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
GB8828477D0 (en) 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
CA2094266C (fr) 1990-10-18 1999-06-01 Robert K. Schultz Formulations
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5190029A (en) * 1991-02-14 1993-03-02 Virginia Commonwealth University Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
US5653961A (en) * 1995-03-31 1997-08-05 Minnesota Mining And Manufacturing Company Butixocort aerosol formulations in hydrofluorocarbon propellant
GEP20002254B (en) * 1995-04-14 2000-10-25 Glaxo Wellcome Inc Metered Dose Inhaler, the Inhaler System Comprising the Same and Method for Treatment of Respiratory Disturbances
GB9612297D0 (en) 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
EP0914143A1 (fr) * 1996-07-08 1999-05-12 Rhone-Poulenc Rorer Limited Formulation d'une solution d'aerosol medicinal de cyclosporine a
GB9620187D0 (en) 1996-09-27 1996-11-13 Minnesota Mining & Mfg Medicinal aerosol formulations
WO1998034595A1 (fr) * 1997-02-05 1998-08-13 Jago Research Ag Formulations medicales pour aerosols
US6126919A (en) * 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
EE05167B1 (et) * 2000-05-22 2009-06-15 Chiesi Farmaceutici S.P.A. Stabiilsed farmatseutilised lahuspreparaadid survestatud doseerivatele inhalaatoritele
DK3384931T3 (da) * 2002-03-01 2019-09-16 Chiesi Farm Spa Superfin formoterolformulering
EP1415647A1 (fr) * 2002-10-23 2004-05-06 CHIESI FARMACEUTICI S.p.A. Beta-2-agonistes à activité de longue durée dans une formulation ultrafine
EP1340492A1 (fr) * 2002-03-01 2003-09-03 CHIESI FARMACEUTICI S.p.A. Formulations d'aérosol pour l'administration par voie pulmonaire de medicaments avec effet systémique

Also Published As

Publication number Publication date
US6713047B1 (en) 2004-03-30
CY1106904T1 (el) 2012-05-23
CA2352483A1 (fr) 2000-06-02
DE69936730T2 (de) 2008-04-30
ZA200104220B (en) 2002-05-23
IT1303788B1 (it) 2001-02-23
AU1555300A (en) 2000-06-13
DE69936730D1 (de) 2007-09-13
DK1133277T3 (da) 2007-12-27
CN1177582C (zh) 2004-12-01
EP1133277A1 (fr) 2001-09-19
JP2002530316A (ja) 2002-09-17
NZ511923A (en) 2003-10-31
TR200101442T2 (tr) 2002-05-21
NO20012517D0 (no) 2001-05-22
ES2289832T3 (es) 2008-02-01
KR100794060B1 (ko) 2008-01-10
CN1331581A (zh) 2002-01-16
AU770529B2 (en) 2004-02-26
WO2000030607A1 (fr) 2000-06-02
CA2352483C (fr) 2009-01-20
EP1133277B1 (fr) 2007-08-01
NO330195B1 (no) 2011-03-07
PT1133277E (pt) 2007-10-09
WO2000030607A8 (fr) 2001-03-22
NO20012517L (no) 2001-07-23
IL143293A0 (en) 2002-04-21
ITMI982558A1 (it) 2000-05-25
KR20010080560A (ko) 2001-08-22
ATE368450T1 (de) 2007-08-15
US20040184993A1 (en) 2004-09-23
BR9916865A (pt) 2001-11-13

Similar Documents

Publication Publication Date Title
MA26763A1 (fr) Composition pharmaceutique d'aerosols contenant hfa 237 & hfa 134a
MXPA02011414A (es) Formulaciones farmaceuticas en solucion estable para inhaladores presurizados con medicion de dosis.
Steckel et al. In vitro evaluation of dry powder inhalers I: drug deposition of commonly used devices
NZ334149A (en) Pharmaceutical aerosol composition containing an active material, a propellant containing a hydrofluoroalkane and a cosolvent and a low volatility component
EA200100338A1 (ru) Способ и устройство для введения действующего вещества в виде аэрозоли в легкие пациента
TNSN04148A1 (en) Aerosol formulations for pulmonary administration of medicaments to produce a systemic effect
BR9406908A (pt) Composição farmacêutica dispositivo inalador processo para administração sistema de um polipeptideo farmaceuticamente ativo para a fabricação e preparação de uma composição farmacêutica e uso de um agente de melhoramento na preparação de uma preparação de po seco inalavel
RU95112536A (ru) Способы пульсирующего системного введения активного фрагмента паратиреоидного гормона (ртн) и фармацевтические композиции, содержащие биологически активный n-концевой фрагмент паратиреоидного гормона (ртн)
IS4178A (is) Lyfjablanda til innöndunar sem inniheldur insúlín
RU94040361A (ru) Аэрозольная фармацевтическая композиция, баллончик для доставки композиции, дозировочный ингалятор, способ лечения респираторных заболеваний, способ получения композиции
AU4260496A (en) Propellant mixture for aerosol formulation
AR009370A1 (es) UNA COMPOSICION FARMACEUTICA EN AEROSOL ADECUADA PARA LA ADMINISTRACION DE BUDESONIDA, UN PRODUCTO FARMACEUTICO QUE LA CONTIENE, UN METODO PARAADMINISTRAR BUDESONIDA Y USO DE UNA MEZCLA DE HFA 134a Y HFA 227
AU2512801A (en) Aerosol inhaler
YU87902A (sh) Stabilne farmaceutske formulacije rastvora za inhalatore odmerene doze pod pritiskom
ATE326220T1 (de) Verabreichungsverfahren von s-adenosylmethionin in form eines mikrofeinen pulvers durch inhalieren
GEP20053649B (en) Stable Pharmaceutical Solution Formulations for Pressurised Metered Dose Inhalers